Susan is a Partner in Gilbert + Tobin’s Competition + Regulation group.
She specialises in competition law with particular expertise advising clients in relation to mergers and acquisitions, collaborations, IP licensing agreements, manufacturing and distribution arrangements and investigations of cartel conduct and concerted practices.
Susan has extensive experience with multijurisdictional matters and in pharmaceuticals and healthcare. Her previous role was the head of the global antitrust practice at Swiss healthcare company Novartis. There she led the merger clearance process for Novartis’s acquisition of eye care company Alcon and for Novartis’s series of high-profile transformational deals with GSK and Lilly (GCR Awards 2015 Matter of the Year).
She is the co-author for the Australian chapter for Lexology/Getting the Deal Through’s “Digital Health 2021” publication and authored a Pharmaceuticals chapter for GCR’s Asia-Pacific Antitrust Review 2021.
Susan was profiled in the Global Competition Review’s Corporate Counsel 2019 quadrennial list of the top inhouse antitrust lawyers in the world. She is also member of the Mergers Working Group of the International Bar Association’s Antitrust Section, the editorial board of the Global Competition Review and is regularly sought out to present at leading global competition conferences.
Our COVID-19 hub collates important coronavirus news, articles and legal advice on various aspects of COVID-19 on how it may impact your business.
Get the latest intel on competition law in Australia and around the world. Join Gilbert + Tobin’s resident experts Moya Dodd and Matt Rubinstein for some lively discussion and debate with special guests.